

Review Article

The pathogenesis of traumatic coagulopathy

A. Cap¹ and B. J. Hunt²

1 Lieutenant Colonel, Medical Corps, US Army and Associate Professor of Medicine, Uniformed Services University, Blood Research Program, US Army Institute of Surgical Research, Sam Houston, Texas, USA

2 Professor of Thrombosis and Haemostasis, Departments of Haematology, Pathology and Lupus, Guy's & St Thomas' NHS Foundation Trust, London, UK

Summary

Over the last 10 years, the management of major haemorrhage in trauma patients has changed radically. This is mainly due to the recognition that many patients who are bleeding when they come in to the emergency department have an established coagulopathy before the haemodilution effects of fluid resuscitation. This has led to the use of new terminology: acute traumatic coagulopathy, acute coagulopathy of trauma shock or trauma-induced coagulopathy. The recognition of acute traumatic coagulopathy is important, because we now understand that its presence is a prognostic indicator, as it is associated with poor clinical outcome. This has driven a change in clinical management, so that the previous approach of maintaining an adequate circulating volume and oxygen carrying capacity before, as a secondary event, dealing with coagulopathy, has changed to haemostatic resuscitation as early as possible. While there is as yet no universally accepted assay or definition, many experts use prolongation of the prothrombin time to indicate that there is, indeed, a coagulopathy. Hypoxia, acidosis and hypothermia and hormonal, immunological and cytokine production, alongside consumption and blood loss, and the dilutional effects of resuscitation may occur to varying extents depending on the type of tissue damaged, the type and extent of injury, predisposing to, or amplifying, activation of coagulation, platelets, fibrinolysis. These are discussed in detail within the article.

Correspondence to: B. Hunt; Email: beverley.hunt@gstt.nhs.uk Accepted: 19 September 2014

Introduction

Trauma remains a major cause of global morbidity and mortality, accounting for over 10% of deaths, with the majority due directly or indirectly to bleeding [1, 2]. Over the last 10 years, the management of major haemorrhage in trauma patients has changed radically. This is mainly due to the recognition that many patients who are bleeding when they come to the emergency department have an established coagulopathy before the dilutional effects of fluid resuscitation. Traumatic coagulopathy has been demonstrated in patients who received little or no intravenous fluid therapy, negating the long-held belief that iatrogenic haemodilution is the main causative factor in trau-

matic coagulopathy [3–6]. This has led to the use of new terminology: acute traumatic coagulopathy (ATC); acute coagulopathy of trauma shock or trauma-induced coagulopathy. In this review, we will use the term ATC. The recognition of ATC is very important because we now understand that its presence is a prognostic indicator, as it is associated with poor clinical outcome [7]. This has driven change in clinical management, so that the previous approach of maintaining an adequate circulating volume and oxygen carrying capacity before, as a secondary event, dealing with coagulopathy, has changed to haemostatic resuscitation as early as possible. However, the type of haemostatic resuscitation varies, with the USA giving

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 01 JAN 2015		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE The pathogenesis of traumatic coagulopathy.				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Cap A., Hunt B. J.,				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Surgical Research, JBSA Fort Sam Houston, Tx 78234				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR	18. NUMBER OF PAGES 9	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

fresh frozen plasma, while there is a different approach in Europe, led by Austria, where fibrinogen concentrates are used and supported by other factor products. The divergence in clinical practice reflects our limited understanding of ATC and comparisons between approaches need to be addressed in clinical trials.

The range of bleeding injuries is wide, and one has to question whether injuries from civilian, compared with military, trauma result in similar haemostatic changes. Military casualties commonly suffer blast injury (primary blast wave, thermal and chemical burns, penetrating fragment wounds, and blunt trauma) from high-energy munitions as well as penetrating trauma from high velocity gunshot wounds. The different mechanisms of injury and increased energy transfer that occur after military trauma may or may not result in different pathophysiological responses when compared with a civilian after a road traffic accident or stab wound. Understanding the admission coagulopathy profile of a military or civilian patient will help to inform future transfusion resuscitation protocols and may help to develop potential medical therapies that will be of benefit. This article summarises the authors' current understanding of the pathogenesis of ATC.

Clinical definition

The concept of ATC stems from the recognition that a prolonged prothrombin time (aPTT) and/or activated partial thromboplastin time (PT) at hospital admission, before resuscitation, is associated with a three to four-fold higher mortality rate and is independently associated with increased transfusion requirements, organ injury, sepsis and critical care length of stay [4]. In two large observational studies, one quarter of trauma patients had prolongation of PT and/or aPTT on admission, which was independently associated with bleeding and death [7]. The development of ATC occurs as a function of the extent of tissue damage and duration of shock.

The tests used to describe ATC have varied between studies, and have included standard plasma-based tests resulting in definitions based on abnormal: aPTT; PT; thrombin time (TT); international normalised ratio (INR); platelet count; fibrinogen level; disseminated intravascular coagulation (DIC) score of 1–4

(non-overt DIC) or ≥ 5 (overt DIC) or abnormalities in clotting amplitude and clot lysis in whole blood visco-elastic tests [5]. While there is as yet no universally accepted assay or definition, many experts use prolongation of the PT to indicate that there is, indeed, a coagulopathy. Ironically, the abnormal test results that have heightened our awareness of ATC may have contributed to well-intentioned but physiologically misguided therapeutic strategies.

Phases of ATC

There are different temporal phases in the evolution of ATC. The first phase is an immediate activation of multiple haemostatic pathways, including fibrinolysis, in association with tissue injury. The second phase is due to resuscitation-related factors, for example the use of colloids and red cells will dilute haemostatic factors; and post-resuscitation, there is an acute phase response leading to a prothrombotic state, predisposing to later venous thromboembolism. In some patients, especially if resuscitated late or inadequately so that there is continuing tissue hypoxia, DIC may ensue.

Immediate effects of tissue injury

The following may occur to varying extent depending on the type of tissue damaged, the type and extent of injury, predisposing to, or amplifying, ATC:

- (1) *Consumption and loss.* Coagulation factors and platelets are consumed during the formation of extravascular clots and thrombus (thrombus is a clot formed within a vessel wall), as well as external loss from the intravascular compartment during bleeding. A reduction in circulating red cells has a major effect on primary haemostasis through reduction in axial blood flow. Red cells usually flow through the centre of an artery or arteriole, and platelets and plasma are pushed to the vessel wall, so that when a vessel is severed the necessary haemostatic factors are close by; this is disrupted once the haematocrit falls below about 30% [8], such that there is an inverse correlation between the haematocrit and in vitro bleeding time [9].
- (2) *Dilution.* The reversal of Starling forces and consequent shifts of interstitial fluid into the vascular

compartment results in autodilution of haemostatic factors. This is aggravated by replacement of lost whole blood with crystalloid, colloid and red cell transfusion. Even so-called balanced transfusion strategies, such as 1:1:1, that attempt to deliver the functionality of whole blood with red cells, plasma and platelets in equal ratios, deliver a dilute final product due to the presence of anticoagulants and red cell additive solutions. The final 1:1:1 product has a haematocrit of 29%, a platelet count of about $80 \times 10^9 \text{ l}^{-1}$ and coagulation factors diluted to 65% of normal. Ultimately, the resultant dilutional coagulopathy is proportional to the volume of fluid administered, both in vitro and in vivo [10, 11].

- (3) *Hormonal and cytokine changes* follow tissue injury. The levels of cytokines and hormones such as epinephrine and vasopressin rise, hormone and thrombin production leads to endothelial cell activation (ECA). Tissue plasminogen activator (t-PA) and Weibel–Palade body contents are released from the endothelium after stimulation by vasopressin. Weibel–Palade bodies anneal with the endothelial wall releasing von Willebrand factor and exposing P-selectin present on their inner wall, onto the surface of the endothelial cell, enhancing platelet recruitment. Cytokines, such as TNF and IL-1 as well as thrombin and continued hypoxia, cause ECA and lead to a slow change in endothelial cell phenotype from antithrombotic to prothrombotic which, in inadequately resuscitated patients, leads to DIC. Endothelial cell activation down-regulates thrombomodulin and fibrinolysis, (PAI-1 levels increase) causing cleavage of glycosaminoglycans and sloughing of the glycocalyx from the cell surface, limiting activation of antithrombin; increases in platelet activating factor production increase endothelial permeability and, in vitro, up-regulates the expression of tissue factor [12, 13].
- (4) *Hypoxia, acidosis and hypothermia*. This triad predisposes to bleeding by impairing the function of platelets and coagulation proteases while increasing fibrinolysis [14]. Hypoxia exacerbates ECA, and coagulopathic changes are most pronounced once the pH is < 7.1 [15] and core temperature is $< 33^\circ \text{C}$ [16].

- (5) *Immune activation*. Tissue damage and shock are associated with platelet release of soluble CD40-ligand, a potent immune activator that itself can cause further ECA and platelet activation, and is known to be necessary in order to stabilise thrombi [29]. Immune stimulation, including complement activation, is associated with release of damage-associated molecular patterns (DAMPs), such as mitochondrial DAMPs and histone-complexed DNA [30, 31]. Immune activation can aggravate tissue damage through mechanisms including proteolytic degradation and oxidative stress, thus amplifying haemostatic activation.

Pathophysiology

Current available evidence suggests that ATC is due to massive stimulation of thrombin generation, fibrinogen and platelet consumption, and fibrinolysis by damaged tissues. Tissue damage exposes tissue factor (TF), which is present on all cells within the body that are not normally in contact with the blood, and also the sub-endothelial matrix. Tissue factor drives localised thrombin and fibrin generation. Collagen within the sub-endothelial matrix binds to platelet glycoprotein VI and vWF to glycoprotein Ib, causing platelet activation. Activated platelets adhere to damaged tissues and serve as catalysts for amplification of thrombin generation. These processes are reflected in the findings of observational clinical studies that show reduced clotting factor and physiological anticoagulant levels [21–23], high thrombin generating capacity [3, 4, 21, 24–26] and reduced platelet counts [27, 28]. Overall, these data indicate a consumptive coagulopathy. The most depleted coagulation factors are fibrinogen and factor V [22, 28], which are likely consumed in part by activated Protein C or free plasmin [29, 30], although the relative importance of these proteases in reducing factor levels remains unknown.

Thrombin is the key effector molecule in haemostasis; its generation not only converts fibrinogen to fibrin but, like a cytokine, it also activates platelets, leucocytes and endothelium. Thrombin is also a major stimulator of endothelial t-PA secretion, an effect previously known as secondary fibrinolysis (as fibrinolytic activation is secondary to coagulation activation). Stimulation of t-PA release from the endothelium by

other factors such as hypoxia, epinephrine and vasopressin, is known as primary fibrinolysis. High t-PA levels have been reported in coagulopathic trauma patients [4, 26]. In addition, when bound to the endothelial receptor, thrombomodulin, thrombin activates Protein C.

It has been proposed that activated protein C (aPC) is a major effector of ATC through cleavage of factors Va and VIIIa. In addition, by binding PAI-1 and de-repressing t-PA, it may activate fibrinolysis [3, 5, 29]. This mechanism is plausible but problematic due to the kinetics of the reactions. Platelets and plasma Factor Va are resistant to aPC cleavage at concentrations of aPC seen in ATC or even therapeutic use of recombinant human aPC in sepsis [31]. As a normal platelet count of $200 \times 10^9 \text{ l}^{-1}$ overcame aPC anticoagulant effects even at very high concentrations of aPC, and there was no detectable effect on fibrinolysis with or without platelets [31], it is difficult to envisage how aPC could drive the phenotype described as ATC. Furthermore, though factor V is depleted and PC converted to aPC in ATC, it has been amply demonstrated that thrombin generation potential is dramatically elevated in trauma patients; this is surely inconsistent with the notion that aPC is inhibiting thrombin generation by inactivating factor V [32]. Also, it must be noted that PAI-1 is a potent inhibitor of aPC in the presence of vitronectin [33]. It is unlikely that inactivation of aPC by vitronectin/PAI-1 would lead to PAI-1 depletion and acceleration of fibrinolysis, as PAI-1 circulates at about ten times higher levels than aPC [34, 35]. It seems more likely that the enormously increased release of t-PA due to epinephrine, vasopressin and thrombin signalling drives the fibrinolytic phenotype of ATC.

The CRASH-2 trial underscored the central role of fibrinolysis in ATC by demonstrating a one-third reduction in death due to haemorrhage in trauma patients given tranexamic acid (TXA), which inhibits activation of plasminogen to plasmin [36, 37]. Other clinical studies have reported that fibrinolytic activation is correlated with transfusions [38] and mortality [38–42]. The plasmin–antiplasmin complex (PAP) is perhaps the most sensitive indicator of fibrinolytic activation, and its levels are increased in approximately 60% of trauma patients [43]. Plasmin activation and

generation of fibrin degradation products such as D-dimers [3, 4, 39, 44–46] are characteristic of bleeding trauma patients. Furthermore, free plasmin can break down coagulation factors, and the extent of this effect has not been fully evaluated in traumatic coagulopathy [47].

The pathophysiology of ATC evolves after the immediate haemostatic effects triggered by tissue injury. Endothelial cell activation, stimulated by thrombin and various cytokines, as well as hypoxia and hypoperfusion [48], generates a prothrombotic environment. Hypoperfusion plays a critical role in the pathogenesis of ATC as demonstrated in numerous clinical studies [3, 6, 42–51], animal models [6, 50] and in vitro experiments [22, 51]. These data indicate that as shock severity increases, the PT and INR rise [4, 5, 7, 52] and coagulation factor levels fall [6, 48]. The most compelling of these studies, that included 3646 patients, demonstrated that ATC (INR > 1.2) occurred only when significant hypoperfusion (base deficit > 6 mmol.l⁻¹) was combined with severe injury (Injury severity score > 15) [6].

As ATC evolves over time, the prothrombotic effects of endothelial cell activation eventually predominate, particularly if hypoxia and acidosis are not alleviated. Many factors contribute, but release of phosphatidylserine positive microvesicles from the endothelium exacerbates the prothrombotic environment [53]. A net production of PAI-1 over t-PA further leads to shutdown of fibrinolysis [4, 25, 45]. This may explain why antifibrinolytic treatment at this stage may worsen outcome [40].

Platelets form the scaffold of clots during primary haemostasis, and serve as the catalysts of coagulation in the current cell-based model of coagulation. Platelets are relatively unresponsive to collagen, ADP and arachidonic acid after trauma [54, 55]. The pathophysiology underlying this dysfunction, which remains obscure, probably explains improved outcomes associated with platelet transfusion despite adequate platelet counts [56, 57]. Lower platelet counts on hospital admission predict trauma mortality, even when within the normal range [58, 59]. Furthermore, outcomes may be determined by the quality of transfused platelets [60].

Cellular microvesicles also contribute to normal haemostasis. Tissue factor initiates clot formation

when P-selectin glycoprotein ligand 1 (PSGL-1)/TF-bearing microvesicles from monocytes interact with P-selectin on platelets attached to injured tissue [61]. This procoagulant microvesicle production increases in trauma [62] and accelerates prothrombotic change [63].

In some ways, the initial changes of ATC are similar to DIC [40, 64]. However, in most trauma patients, there is no evidence of inappropriate disseminated clot formation on histological examination [65], so early ATC is not DIC.

The importance of rapidly identifying coagulopathy

Severely injured patients are more likely to suffer from haemorrhagic shock, require massive transfusions, and are at high risk of death due to bleeding. Acute traumatic coagulopathy is the key pathophysiological derangement, driven by tissue damage, which results in TF exposure, shock and hypoxia, and must be mitigated to successfully resuscitate the patient [66, 67].

Predicting coagulopathy

Scoring systems have been developed for adult and paediatric trauma populations that predict which patients will develop severe haemorrhage and require massive resuscitation. Algorithms based on these scores shift clinical management from a reactive to a proactive stance [66–71]. Unfortunately, none of these scoring systems identify all patients at risk of ATC and death due to bleeding. Therefore, it should be assumed that any patient considered at risk of exsanguination is at risk of ATC and death [70].

Current methods for ATC diagnosis and their pitfalls

Standard coagulation tests

These include PT-based tests (PT, INR), aPTT and Clauss fibrinogen. The PT/INR is considered an adequate screen for multiple coagulation factor deficiencies, and was thus adopted as a marker of ATC [28]. Every laboratory can provide PT, aPTT and fibrinogen results, and they are useful in guiding transfusion and predicting mortality [51].

Originally, these tests were designed to evaluate clotting factor deficiencies, not acquired multiple fac-

tor-based coagulopathies, and they are not predictors of bleeding in these circumstances [72]. Moreover, they do not take into consideration the contribution of platelets to haemostasis, the role of fibrinolysis, thrombin generation, or the interactions between coagulation enzymes and cellular phospholipid surfaces. Furthermore, these are not point-of-care assays and turnaround times often negate the value of the results [5]. Therefore, plasma-based coagulation assays are rarely helpful in the immediate management of ATC, but they do have an important role in monitoring ongoing bleeding, to guide the use of appropriate blood products.

Thromboelastography and thromboelastometry

Increasingly, TEG[®] (Hemonetics Corporation, Braintree, MA, USA) and ROTEM[®] (TEM International GmbH, Munich, Germany) are being used to guide trauma resuscitation [38, 41]. Minimally injured patients tend to have normal profiles, whereas moderately or severely injured patients typically exhibit TEG changes [38, 46]. Thromboelastography and ROTEM can play a role in the diagnosis of severe fibrinolysis, but are insensitive to more limited fibrinolytic activity [73]. Marked fibrinolysis detected by TEG or ROTEM is associated with a poor prognosis. Schöchl et al. [41] and others have defined hyperfibrinolysis as a reduction in maximal amplitude (MA) of 15% on ROTEM testing. However, this definition conflicts with the classic understanding of hyperfibrinolysis, which describes a kinetic reversal whereby fibrinolytic activity is greater than fibrin formation, and clot strength is compromised [74]. Thromboelastographic hyperfibrinolysis should perhaps be used to describe increased lysis only in relation to TEG visco-elastic measurements.

There is no commonly accepted visco-elastic definition of ATC, although the candidates include: increases in clotting time and clot formation time; and loss of clot amplitude (CA) and maximal clot amplitude [40, 50, 75]. One group used ROTEM to define an EXTEM CA5 (CA at 5 min) value of < 36 mm as diagnostic of ATC [5]. Another group suggests that TEG or ROTEM A10 correlates well with platelet count and fibrinogen level and predicts transfusion requirements. Advocates for visco-elastic monitoring suggest that the capacity to distinguish specific haemo-

static abnormalities provides a means of individualising coagulation and transfusion management [37, 41]. However, there are no ROTEM and TEG algorithms validated by randomised trials. Another important limitation is that, like other standard coagulation tests, TEG and ROTEM are typically performed at 37 °C, and results underestimate coagulation disturbances in hypothermic patients.

The evolving importance of ATC in trauma resuscitation

The recognition of ATC has driven dramatic change in trauma management. Until the military experience in Iraq and Afghanistan was published over the last 10 years, resuscitation was started with red cell concentrates, and scant attention was paid to coagulopathy until much later. Retrospective data from the USA and UK military and leading civilian institutions described improved outcomes in those treated with fresh whole blood [76–78] or fresh frozen plasma (FFP), cryoprecipitate and platelets in combination with red cells and tranexamic acid, with extremely limited use of colloid or crystalloid infusions [76–82], a practice known as haemostatic resuscitation [83]. It is possible that current transfusion strategies can be optimised to further improve survival after ATC [84]; the results of randomised controlled trials will guide further developments [85]. In North America, the challenge of managing ATC has generated renewed interest in whole blood for trauma resuscitation [86–89]. On the other hand, in some European countries, fibrinogen and other factor concentrates have replaced FFP in the management

of ATC [90]. The evolution of divergent clinical practices underscores the need for a better understanding of the pathophysiology of ATC and for more clinical research looking at the full risks and benefits of improved haemostatic management. For example, there are no studies looking at the effect of modern treatment on the rate of post-trauma venous thromboembolism, which is a major cause of morbidity and mortality. It is recognised that the use of prothrombin complex concentrate may induce later prothrombotic changes [91], and potentially this may affect the rate of posttrauma thromboembolism.

Conclusion

Over the last decade, the incidence and implications of ATC have become clearer to the trauma community. Further clinical studies are required to increase our understanding of the pathophysiology of traumatic coagulopathy and inform the direction of studies to improve haemostatic management and outcomes.

Acknowledgements

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of the Army or the US Department of Defence.

Competing interests

No external funding and no competing interests declared.

References

1. WHO. World Health Organisation. Global Health Indicators, 2011. http://www.who.int/whosis/whostat/EN_WHS2011_Part2.pdf (accessed 17/09/2014).
2. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001–2011): implications for the future of combat casualty care. *Journal of Trauma and Acute Care Surgery* 2012; **73**: S431–7.
3. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet J-F. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? *Annals of Surgery* 2007; **245**: 812–8.
4. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. *Journal of Trauma* 2008; **64**: 1211–7.
5. Davenport R, Manson J, De'Ath H, et al. Functional definition and characterization of acute traumatic coagulopathy. *Critical Care Medicine* 2011; **39**: 2652–8.
6. Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. *Journal of Thrombosis and Haemostasis* 2010; **8**: 1919–25.
7. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *Journal of Trauma* 2003; **54**: 1127–30.
8. Valeri CR, Khuri S, Ragno G. Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasmin-clotting proteins. *Transfusion* 2007; **47**: S206–48.
9. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. *Thrombosis and Haemostasis* 2005; **94**: 1213–8.
10. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. *British Journal of Anaesthesia* 2009; **102**: 793–9.
11. Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. *Injury* 2007; **38**: 298–304.
12. Hunt BJ, Jurd KM. Endothelial cell activation. *British Medical Journal* 1998; **316**: 1328–9.
13. Johansson PI, Sorensen AM, Perner A, et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? A prospective observational study. *Critical Care* 2011; **15**: R272.
14. Dirkmann D1, Radü-Berleemann J, Görlinger K, Peters J. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid. *Journal of Trauma and Acute Care Surgery* 2013; **74**: 482–8.
15. Martini WZ, Pusateri AE, Uscilowicz JM, Delgado AV, Holcomb JB. Independent contributions of hypothermia and acidosis to coagulopathy in swine. *Journal of Trauma* 2005; **58**: 1002–9.
16. Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. *Journal of Trauma* 2004; **56**: 1221–8.
17. Andre P, Srinivasa P, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. *Nature Medicine* 2002; **8**: 24752.
18. Johansson PI, Windeløv NA, Rasmussen LS, Sørensen AM, Ostrowski SR. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. *Journal of Thrombosis and Haemostasis* 2012; **10**: 207–16.
19. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* 2010; **464**: 104–7.
20. Johansson PI, Sørensen AM, Perner A, et al. Blood levels of histone-complexed DNA fragments are associated with coagulopathy, inflammation and endothelial damage early after trauma. *Journal of Emergencies, Trauma and Shock* 2013; **6**: 171–5.
21. Floccard B, Rugeri L, Faure A, et al. Early coagulopathy in trauma patients: an on-scene and hospital admission study. *Injury* 2012; **43**: 26–32.
22. Jansen JO, Scarpelini S, Pinto R, Tien HC, Callum J, Rizoli SB. Hypoperfusion in severely injured trauma patients is associated with reduced coagulation factor activity. *Journal of Trauma* 2011; **71**: S435–40.
23. Shaz BH, Winkler AM, James AB, Hillyer CD, MacLeod JB. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. *Journal of Trauma* 2011; **70**: 1401–7.
24. Dunbar NM, Chandler WL. Thrombin generation in trauma patients. *Transfusion* 2009; **49**: 2652–60.
25. Chandler W. Procoagulant activity in trauma patients. *American Journal of Clinical Pathology* 2010; **134**: 90–6.
26. Hayakawa M, Sawamura A, Gando S, et al. Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. *Surgery* 2011; **149**: 221–30.
27. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. *Journal of Trauma* 2003; **55**: 39–44.
28. Yuan S, Ferrell C, Chandler WL. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. *Thrombosis Research* 2007; **120**: 29–37.
29. Cohen MJ, Call M, Nelson M, et al. Critical role of activated Protein C in early coagulopathy and later organ failure, infection and death in trauma patients. *Annals of Surgery* 2012; **255**: 379–85.
30. Omar MN, Mann KG. Inactivation of factor Va by plasmin. *Journal of Biological Chemistry* 1987; **262**: 9759–5.
31. Campbell JE, Meledeo MA, Cap AP. Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy. *PLoS ONE* 2014; **9**: e99181.
32. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. *Journal of Biological Chemistry* 2001; **276**: 15567–70.
33. Cardenas JC, Rahbar E, Pommerening MJ, et al. Measuring thrombin generation as a tool for predicting hemostatic potential and transfusion requirements following trauma. *Journal of Trauma and Acute Care Surgery* DOI: 10.1097/TA.0000000000000348.
34. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. *Journal of Thrombosis and Haemostasis* 2005; **3**: 35–45.
35. Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. *Journal of Thrombosis and Haemostasis* 2007; **5**: S73–80.
36. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma

- patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010; **376**: 23–32.
37. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. *Lancet* 2011; **377**: 1096–101.
38. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. *Annals of Surgery* 2010; **252**: 434–42.
39. Levrat A, Gros A, Rugeri L, Floccard B, Negrier C, David J-S. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. *British Journal of Anaesthesia* 2008; **100**: 792–7.
40. Sawamura A, Hayakawa M, Gando S, et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. *Thrombosis Research* 2009; **124**: 608–13.
41. Schöchl H, Frietsch T, Pavelka M, Jámor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. *Journal of Trauma* 2009; **67**: 125–31.
42. Schöchl H, Nieber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. *Critical Care* 2010; **14**: R55.
43. Hunt BJ, Raza I, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients: a reply to a rebuttal. *Journal of Thrombosis and Haemostasis* 2013; **11**: 1437–8.
44. Kushimoto S, Gando S, Saitoh D, et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. *Thrombosis and Hemostasis* 2008; **100**: 1099–105.
45. Chen JP, Rowe DW, Enderson BL. Contrasting post-traumatic serial changes for D-dimer and PAI-1 in critically injured patients. *Thrombosis Research* 1998; **94**: 175–85.
46. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. *Journal of Hemostasis and Thrombosis* 2007; **5**: 289–95.
47. Nogami K, Shima M, Matsumoto T, Nishiya K, Tanaka I, Yoshioka A. Mechanism of plasmin-catalyzed inactivation of Factor VIII. *Journal of Biological Chemistry* 2007; **282**: 5287–95.
48. Faller DV. Endothelial cell responses to hypoxic stress. *Clinical and Experimental Pharmacology and Physiology* 1999; **26**: 74–84.
49. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. *Journal of Trauma* 2008; **64**: 1459–65.
50. Darlington DN, Craig T, Gonzales MD, Schwacha MG, Cap AP, Dubick MA. Acute coagulopathy of trauma in the rat. *Shock* 2013; **39**: 440–6.
51. Pinky DJ, Yan SF, Lawson C, et al. Hypoxia and modification of the endothelium: implications for regulation of vascular homeostatic properties. *Seminars in Cellular Biology* 1995; **6**: 283–94.
52. Komissarov AA, Andreasen PA, Declerck PJ, Kamikubo Y, Zhou A, Gruber A. Redirection of the reaction between activated protein C and a serpin to the substrate pathway. *Thrombosis Research* 2008; **122**: 397–404.
53. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freysinet JM, Tedgui A. Endothelial microparticles in diseases. *Cell and Tissue Research* 2009; **335**: 143–51.
54. Castellino FJ, Chapman MP, Donahue DL, et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. *Journal of Trauma and Acute Care Surgery* 2014; **76**: 1169–76.
55. Kutcher ME, Redick BJ, McCreery RC, et al. Characterization of platelet dysfunction after trauma. *Journal of Trauma and Acute Care Surgery* 2012; **73**: 13–9.
56. Perkins JG, Cap AP, Spinella PC, et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. *Journal of Trauma* 2009; **66**: S77–84.
57. Zink KA, Sambasivan CN, Holcomb JB, Chisholm G, Schreiber MA. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. *American Journal of Surgery* 2009; **197**: 565–70.
58. Brown LM, Call MSM, Margaret Knudson MC, Cohen MJ. Trauma Outcomes Group. A normal platelet count may not be enough: the impact of admission platelet count on mortality and transfusion in severely injured trauma patients. *Journal of Trauma* 2011; **71**: S337–42.
59. Stansbury LG, Hess AS, Thompson K, Kramer B, Scalea TM, Hess JR. The clinical significance of platelet counts in the first 24 hours after severe injury. *Transfusion* 2013; **53**: 783–9.
60. Inaba K, Branco BC, Rhee P, et al. Impact of the duration of platelet storage in critically ill trauma patients. *Journal of Trauma* 2011; **71**: 1766–73.
61. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. *Journal of Experimental Medicine* 2003; **197**: 1585–98.
62. Morel N, Morel O, Petit L, et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. *Journal of Trauma* 2008; **64**: 698–704.
63. Park MS, Owen BA, Ballinger BA, et al. Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. *Surgery* 2012; **151**: 831–6.
64. Gando S, Sawamura A, Hayakawa M. Trauma, shock and disseminated intravascular coagulation: lessons from the classical literature. *Annals of Surgery* 2011; **254**: 10–9.
65. Rizoli S, Nascimento B, Key N, et al. Disseminated Intravascular Coagulopathy in the first 24 hours after trauma: the association between ISTH score and anatomopathologic evidence. *Journal of Trauma* 2011; **71**: S441–7.
66. Maegele M, Lefering R, Wafaisade A, et al. Revalidation and update of the TASH-Score: a scoring system to predict the probability for massive transfusion as a surrogate for life-threatening haemorrhage after severe injury. *Vox Sanguinis* 2011; **100**: 231–8.
67. Cancio LC, Wade CE, West SA, Holcomb JB. Prediction of mortality and of the need for massive transfusion in casualties arriving at combat support hospitals in Iraq. *Journal of Trauma* 2008; **64**: S51–6.
68. Ruchholtz S, Pehle B, Lewan U, et al. The emergency room transfusion score (ETS): prediction of blood transfusion requirement in initial resuscitation after severe trauma. *Transfusion Medicine* 2006; **16**: 49–56.
69. Schreiber MA, Perkins J, Kiraly L, Underwood S, Wade C, Holcomb JB. Early predictors of massive transfusion in combat casualties. *Journal of the American College of Surgery* 2007; **205**: 541–5.

70. Yücel N, Lefering R, Maegele M, et al. Trauma associated severe hemorrhage (TASH)-score: probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. *Journal of Trauma* 2006; **60**: 1228–37.
71. Reed MJ, Lone N, Walsh TS. Resuscitation of the trauma patient: tell me a trigger for early haemostatic resuscitation please!. *Critical Care* 2011; **15**: 126.
72. Dziki WH. Predicting hemorrhage using preoperative coagulation screening assays. *Current Hematology Reports* 2004; **3**: 324–30.
73. Raza I, Davenport R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. *Journal of Thrombosis and Haemostasis* 2013; **11**: 307–14.
74. Hunt BJ, Segal H. Hyperfibrinolysis. *Journal of Clinical Pathology* 1996; **49**: 958.
75. Carroll RC, Craft RM, Langdon RJ, et al. Early evaluation of acute traumatic coagulopathy by thromboelastography. *Translational Research* 2009; **154**: 34–9.
76. Spinella PC, Holcomb JB. Resuscitation and transfusion principles for traumatic hemorrhagic shock. *Blood Reviews* 2009; **23**: 231–40.
77. Perkins JG, Cap AP, Spinella PC, et al. 31st Combat Support Hospital Research Group. Comparison of platelet transfusion as fresh whole blood versus apheresis platelets for massively transfused combat trauma patients. *Transfusion* 2011; **51**: 242–52.
78. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects the mortality in patients receiving massive transfusions at a combat support hospital. *Journal of Trauma* 2007; **63**: 805–13.
79. Pidcock HF, Aden JK, Mora AG, et al. Ten-year analysis of transfusion in Operation Iraqi Freedom and Operation Enduring Freedom: increased plasma and platelet use correlates with improved survival. *Journal of Trauma and Acute Care Surgery* 2012; **73**: S445–52.
80. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. *Critical Care* 2013; **17**: R76.
81. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. *Journal of Thrombosis and Haemostasis* 2012; **10**: 1342–51.
82. Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERS II Study. *Journal of the American Medical Association Surgery* 2013; **148**: 218–25.
83. Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets – a review of the current literature. *Transfusion* 2010; **50**: 701–10.
84. Khan S, Brohi K, Chana M, et al. International Trauma Research Network (INTRN). Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. *Journal of Trauma and Acute Care Surgery* 2014; **76**: 561–7; discussion 567–8.
85. Holcomb JB, Pati S. Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective. *American Society of Hematology Education Program* 2013; **2013**: 656–9.
86. Spinella PC, Reddy HL, Jaffe JS, Cap AP, Goodrich RP. Fresh whole blood use for hemorrhagic shock: preserving benefit while avoiding complications. *Anesthesia and Analgesia* 2012; **115**: 751–8.
87. Cotton BA1, Podbielski J, Camp E, et al. Early Whole Blood Investigators. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. *Annals of Surgery* 2013; **258**: 527–32.
88. Murdock AD, Berséus O, Hervig T, Strandenes G, Lunde TH. Whole blood: the future of traumatic hemorrhagic shock resuscitation. *Shock* 2014; **41**: 62–9.
89. Cap AP. The school of hard knocks: what we've learned and relearned about transfusion in a decade of global conflict. *Transfusion Medicine* 2014; **24**: 135–7.
90. Coagulation management in trauma-related massive bleeding – Recommendations of the Task Force for Coagulation (AGPG) of the Austrian Society of Anesthesiology, Resuscitation and Intensive Care Medicine (OGARI). *Anesthesiologie und Intensivmedizin Notfallmed Schmerzther* 2010; **45**: 552–61.
91. Schöchl H, Voelckel W, Maegele M, Kirchmair L, Schlömp CJ. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. *Critical Care* 2014; **18**: R147.